Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan

@article{Chou1999BindingOD,
  title={Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan},
  author={Yueh-Ching Chou and Jyh Fei Liao and Wan-Ya Chang and Ming-fang Lin and Chieh-fu Chen},
  journal={Brain Research},
  year={1999},
  volume={821},
  pages={516-519}
}
Dextromethorphan ((+)-3-methoxy-N-methylmorphinan, DM) has been shown to have both anticonvulsant and neuroprotective effects. The mechanisms of these CNS effects of DM have been suggested to be associated with the low-affinity, noncompetitive, N-methyl-d-aspartate (NMDA) antagonism of DM and/or the high-affinity DM/sigma receptors. DM is largely O-demethylated into the phencyclidine (PCP)-like compound dextrorphan (DR), which may limit its therapeutic use by producing PCP-like adverse effects… 
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
TLDR
Data suggest that dextromethorphan exerts some of its antidepressant actions through σ1 receptors, which has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate receptor antagonist ketamine.
NMDA-receptor antagonism via dextromethorphan and ifenprodil modulates graded anxiety test performance of C57BL/6 mice
TLDR
The majority of N-methyl-D-aspartate receptors (NMDA-R) in the adult forebrain are di- or triheteromers composed of NR1, NR2A and NR2B subunits, so the anxiolytic potential of NMDA subunit non-selective agents might involveNR2A-containing receptors.
An Efficient Synthesis of Dimemorfan from Dextromethorphan
Dimemorfan [(C)-3-methyl-N-methylmorphinan, DF], widely used as an antitussive drug without narcotic effects, is an analogue of dextromethorphan [(C)-3-methoxyN-methylmorphinan, DM]. However, it is
The dextromethorphan analog dimemorfan attenuates kainate‐induced seizures via σ1 receptor activation: comparison with the effects of dextromethorphan
TLDR
The results suggest that dimemorfan is equipotent to dextromethorphan in preventing KA‐induced seizures, while it may lack behavioral effects, such as psychotomimetic reactions.
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice
TLDR
The results suggest that dimemorfan is equipotent to dextromethorphan in preventing BAY k-8644-induced seizures, while it lacks behavioral side effects related to psychotomimetic reactions.
Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice
TLDR
The data indicate that low-affinity, clinically available and/or therapeutically promising NMDA receptor antagonists may be used to inhibit ongoing morphine tolerance.
Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats
TLDR
The results suggest that alpha3beta4* nicotinic receptors do not play a major role in nicotine's discriminative stimulus effects and suggest that the role of cholinergic mediation of the behavioral effects of dextrorphan and dextromethorphan related to the abuse properties of nicotine may be minimal.
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
TLDR
The findings suggest that DM/Q likely inhibits serotonin and norepinephrine reuptake and also blocks NMDA receptors with rapid kinetics, and may also antagonize nicotinic acetylcholine receptors, particularly those composed of α3β4 subunits, and cause agonist activity at sigma-1 receptors.
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
TLDR
The results suggest that the therapeutic window for dextromethorphan in the clinical population is small as similar doses produce antidepressant-like and anxiogenic-like behaviors.
Dextromethorphan Potentiates Morphine-Induced Antinociception at both Spinal and Supraspinal Sites but Is Not Related to the Descending Serotoninergic or Adrenergic Pathways
Morphine is a strong and widely used opioid analgesic in pain management, but some adverse effects limit its clinical use at high doses. The clinically available non-opioid antitussive,
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile.
TLDR
The results of this study establish these 3-substituted DM analogs as novel anticonvulsants exhibiting improved potency, efficacy, duration and side-effect profiles.
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
TLDR
Dextromethorphan (1,(+)-3-methoxy-17-methylmorphinan) demonstrates anticonvulsant activity in a variety of in vitro and in vivo models of convulsive action and it appears that interaction at the [3H]1 sites may be involved.
High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments.
TLDR
Although the nature of central DM binding sites is not known, the potent interaction of several classes of centrally acting antitussives with DM sites suggests that they may be related to the mechanism of action of this drug.
Antitussive activity and other related pharmacological properties of d-3-methyl-N-methylmorphinan (AT-17).
TLDR
Antitussive activity and some other related pharmacological properties of d-3-methyl-N-methylmorphinan were studied and showed no relaxing effect on the bronchial muscle of guinea pigs in either normal tone or histamine-induced spasms.
Dextromethorphan inhibits NMDA-induced convulsions.
TLDR
The results are consistent with the interpretation that dextromethorphan elicits some of its pharmacological responses via an interaction with receptors for excitatory amino acids.
Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands.
TLDR
Several of these novel compounds are potent, sigma 1-selective ligands which can now be investigated as potential antitussive, anticonvulsant, and antiischemic agents.
Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan
TLDR
The behavioral effects of dextromethorphan, dextrorphan (DO) and phencyclidine (PCP) were compared in rats and the recently reported abuse of DM in humans may occur by its conversion to DO in the organism, i.e., to a metabolite which produces PCP-like effects.
Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-d-aspartic acid antagonism
Various compounds that have been identified in the literature as binding to the [3H]phencyclidine receptor site and as producing behavioral effects similar to phencyclidine (phencyclidine-like)
Dextromethorphan and neuromodulation: old drug coughs up new activities.
TLDR
The CNS pharmacology of dextromethorphan, its possible involvement with NMDA or sigma-receptors, and the potential clinical importance of this old 'new' drug are reviewed.
Dextromethorphan analogs are neuroprotective in vitro and block glutamate-induced excitotoxic calcium signals in neurons
TLDR
A new class of compounds related to DM are established which, by virtue of their efficacy to protect neurons against a severe glutamate insult, may possess therapeutic potential as treatment modalities for a number of neurodegenerative diseases.
...
1
2
3
...